Jump to content

Sulfinpyrazone

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Jytdog (talk | contribs) at 19:18, 30 May 2016 (Undid revision 722852607 by 79.74.20.70 (talk) revert unsourced observation by sock of blocked user Nuklear). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Sulfinpyrazone
Clinical data
Trade namesApo-sulfinpyrazone
AHFS/Drugs.comMonograph
MedlinePlusa682339
Routes of
administration
oral intravenous
ATC code
Pharmacokinetic data
Protein binding98–99%
Metabolismhepatic
Excretionrenal
Identifiers
  • 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.325 Edit this at Wikidata
Chemical and physical data
FormulaC23H20N2O3S
Molar mass404.48 g/mol g·mol−1
3D model (JSmol)
  • O=C2N(c1ccccc1)N(C(=O)C2CCS(=O)c3ccccc3)c4ccccc4
  • InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2 checkY
  • Key:MBGGBVCUIVRRBF-UHFFFAOYSA-N checkY
  (verify)

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.

Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.

Contraindications

Sulfinpyrazone must not be used in persons with renal impairment or a high rate of excretion of uric acid (hyperuricosuria).[1]

References

  1. ^ Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.